NasdaqCM - Nasdaq Real Time Price USD
Aldeyra Therapeutics, Inc. (ALDX)
As of 9:33 AM EST. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
43,049.82
42,794.08
62,679.99
56,219.54
34,666.76
Operating Income
-43,049.82
-42,794.08
-62,679.99
-56,219.54
-34,666.76
Net Non Operating Interest Income Expense
5,180.29
5,251.57
655.35
-1,556.74
-1,611.97
Other Income Expense
--
--
--
--
-1,754.27
Pretax Income
-37,869.53
-37,542.51
-62,024.64
-57,776.27
-38,032.99
Tax Provision
--
--
--
--
-479.27
Net Income Common Stockholders
-37,869.53
-37,542.51
-62,024.64
-57,776.27
-37,553.73
Diluted NI Available to Com Stockholders
-37,869.53
-37,542.51
-62,024.64
-57,776.27
-37,553.73
Basic EPS
-0.64
-0.64
-1.06
-1.07
-1.11
Diluted EPS
-0.64
-0.64
-1.06
-1.07
-1.11
Basic Average Shares
59,254.57
58,943.21
58,405.90
54,042.10
33,965.96
Diluted Average Shares
59,254.57
58,943.21
58,405.90
54,042.10
33,965.96
Total Operating Income as Reported
-43,049.82
-42,794.08
-62,679.99
-56,219.54
-36,421.02
Total Expenses
43,049.82
42,794.08
62,679.99
56,219.54
34,666.76
Net Income from Continuing & Discontinued Operation
-37,869.53
-37,542.51
-62,024.64
-57,776.27
-37,553.73
Normalized Income
-37,869.53
-37,542.51
-62,024.64
-57,776.27
-35,821.92
Interest Income
7,209.43
7,323.01
2,349.45
185.36
292.22
Interest Expense
2,029.14
2,071.44
1,694.10
1,742.10
1,904.20
Net Interest Income
5,180.29
5,251.57
655.35
-1,556.74
-1,611.97
EBIT
-35,840.39
-35,471.08
-60,330.54
-56,034.17
-36,128.80
EBITDA
-35,586.66
-35,208.30
-60,071.83
-55,769.99
-36,072.58
Reconciled Depreciation
253.73
262.78
258.71
264.18
56.22
Net Income from Continuing Operation Net Minority Interest
-37,869.53
-37,542.51
-62,024.64
-57,776.27
-37,553.73
Total Unusual Items Excluding Goodwill
--
--
--
--
-1,754.27
Total Unusual Items
--
--
--
--
-1,754.27
Normalized EBITDA
-35,586.66
-35,208.30
-60,071.83
-55,769.99
-34,318.31
Tax Rate for Calcs
--
--
--
--
0.00
Tax Effect of Unusual Items
--
--
--
--
-22.45
12/31/2020 - 5/2/2014
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ARDX Ardelyx, Inc.
6.37
-1.85%
CTMX CytomX Therapeutics, Inc.
1.0100
+1.00%
ABUS Arbutus Biopharma Corporation
3.8750
-1.15%
ADVM Adverum Biotechnologies, Inc.
7.98
+0.50%
OCUL Ocular Therapeutix, Inc.
10.97
+0.27%
KALA KALA BIO, Inc.
6.99
-0.36%
PHAT Phathom Pharmaceuticals, Inc.
17.34
-3.67%
CAPR Capricor Therapeutics, Inc.
19.15
+5.10%
ABEO Abeona Therapeutics Inc.
6.32
+0.68%
VNDA Vanda Pharmaceuticals Inc.
4.9700
+1.64%